CoChat

Clinical Trials of Diabetic Neuropathy: Past, Present, and Future

Pfeifer, Michael A, Schumer, Mary P · 1995 · Diabetes
Cited by 115

The DOI matches its Crossref record.

Abstract

This article reviews current knowledge of the etiology of diabetic neuropathy and the outcomes and limitations of previous trials and discusses future directions for the investigation of its prevention and treatment. Proposed mechanisms for the development of diabetic neuropathy have been widely studied. It has been shown that there is improvement of nerve function associated with some short-term clinical trials of treatments that address a number of possible etiologic pathways. Improvement of morphometry has also been demonstrated in some short-term clinical trials. However, with the exception of the Diabetes Control and Complications Trial (DCCT), long-term trials with adequate statistical power to evaluate clinical outcome endpoints have not been conducted. The changes in nerve function are similar in most of the clinical trials. For instance, in four clinical trials directed at separate mechanisms (improved glucose control, high myo-inositol diet, therapy with an aldose reductase inhibitor, and therapy with supplementary γ-linolenic acid), a similar improvement in peroneal motor velocity of 1–2 m/s is observed. This implies that each of the proposed mechanisms contributes equally to the development of neuropathy or that there is some redundancy to their mechanisms. In addition to an etiologic approach, nonspecific neural stimulants, such as gangliosides and nerve growth factors, have also been investigated for the treatment of diabetic neuropathy. With the exception of the prevention of neuropathy by intensive glycemic control, the modest improvements with all other treatments have not led to sufficient evidence to approve any approach. Subanalyses of previous clinical trials suggest that treatment effects are greatest and most clear in patients with mild-to-moderate early neuropathy (stage I or early stage II). Thus, variation in composition and severity of baseline neuropathic disease inpast clinical trials may have “washed out” any potential treatment effect. It is encouraging that more recent clinical trials have established more rigid inclusion and exclusion criteria so as to recruit only those patients with early or mild-to-moderate disease and a more homogeneous study population. Improvement with treatment has been measured with several markers including nerve conduction velocity, quantitative sensory testing, autonomic function testing, and morphometric changes. Presumably, the combined finding of improved nerve function and improved nerve morphometry will predict improvement in long-term clinical outcomes such as impaired sensation, painful neuropathy, insensitive feet, neurotrophic ulceration, and/or amputation. However, data to support this possibility are still lacking. It is our opinion that the overall design of neuropathy trials must consider present knowledge about complications in general and neuropathy specifically. We recommend that future trials be conducted over long periods with clinically significant outcomes as in the angiotensin-converting enzyme-inhibitor nephropathy trials and the DCCT with the recognition that reducing the development, rather than reversal, of complications is the best thatcan be reasonably expected. Patients with mild-to-moderate neuropathy (stage I or early stage II) with presumably more metabolic than structural neuropathy would be preferred subjects, and follow-up of 3–5 years is likely to be needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diab.44.12.1355

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Pfeifer, M. A., & Schumer, M. P.
Venue
Diabetes
Published
1995-12-01
Volume
44
Issue
12
Pages
1355-1361
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2163205990
Cited by
115
References
0
FWCI
4.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.